Chilblain lupus erythematosus (CHLE) is a rare type of cutaneous lupus erythematosus (CLE). Symptoms, such as lesions and swelling, can develop after exposure to cold temperatures. CHLE may have a ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and disease flares, according to a study.“[Cutaneous lupus erythematosus (CLE)], ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

Your gut microbiome can trigger an immune response, leading to chronic systemic inflammation and lupus. Here are some tips to ...

Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

Cutaneous lupus erythematosus (CLE) is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD).

A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Hypoglycemia (low blood sugar) is not a formal symptom of lupus, but it may develop from related factors like medication use, other autoimmune processes in the body, and hormonal changes.